




The relative strengths and weaknesses of Achillion Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Achillion Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 141% points. The greatest weakness of Achillion Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 360%, being 106% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	154,875
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,059
Liabilities, Non-Current	279
Other Assets	206
Other Compr. Net Income	-18
Other Expenses	37
Other Liabilities	0
Other Net Income	455
Other Revenues	0
Property and Equipment	1,726
Research and Development	53,515
Selling, General and Administrative Expense	15,911

Output Variable	Value in 1000 USD
Assets	156,807
Liabilities	13,338
Expenses	69,463
Revenues	0
Stockholders Equity	143,469
Net Income	-69,008
Comprehensive Net Income	-69,017
BaseVar	120,040
ECR before LimitedLiability	287%
Economic Capital Ratio	360%